Epilepsy & Behavior 90 (2019) 15–19

Contents lists available at ScienceDirect

Epilepsy & Behavior

journal homepage: www.elsevier.com/locate/yebeh

Lipid and thyroid hormone levels in children with epilepsy treated with levetiracetam or carbamazepine: A prospective observational study

Masahiro Nishiyama [a,*], Yuichi Takami [b], Yusuke Ishida [a,c], Kazumi Tomioka [a], Tsukasa Tanaka [a,c], Hiroaki Nagase [a], Taku Nakagawa [b], Shoichi Tokumoto [a,c], Hiroshi Yamaguchi [a,c], Daisaku Toyoshima [c], Azusa Maruyama [c], Kandai Nozu [a], Noriyuki Nishimura [a], Kazumoto Iijima [a]

[a] Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2, Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo 650-0017, Japan
[b] Department of Pediatrics, Japanese Red Cross Society Himeji Hospital, 1-12-1, Shimoteno, Himeji, Hyogo 670-8540, Japan
[c] Department of Neurology, Hyogo Prefectural Kobe Children's Hospital, 1-6-7, Minatojima-minamimachi, Kobe, Hyogo 650-0047, Japan

ARTICLE INFO

Article history:
Received 1 October 2018
Revised 30 October 2018
Accepted 1 November 2018
Available online 27 November 2018

Keywords:
Antiepileptic drugs
Levetiracetam
Carbamazepine
Children
Thyroid hormone
Lipid

ABSTRACT

Although previous studies have investigated the influence of antiepileptic drugs (AEDs) on lipid profiles and thyroid hormone levels, there is little evidence regarding the effects of levetiracetam (LEV). Therefore, we conducted a prospective longitudinal study to evaluate the effects of LEV and carbamazepine (CBZ) treatment on lipid profile and thyroid hormone levels in patients newly diagnosed with epilepsy. Inclusion criteria were as follows: (a) age between 4 and 15 years, (b) diagnosis of epilepsy with at least two focal seizures within a year, and (c) newly treated with LEV or CBZ monotherapy. Serum lipid profile and thyroid hormone levels were measured before and after 1 and 6 months of AED initiation. Among the 21 included patients (LEV: 13 patients, CBZ: 8 patients), all but one patient in the LEV group continued AED monotherapy during the study period. Although triglyceride (TG) levels tended to be increased in the CBZ group (baseline: 58.3 ± 22.0 mg/dl, 1 month: 63.8 ± 21.6 mg/dl, 6 months: 92.3 ± 63.6 mg/dl, $p = 0.22$, analyses of variance (ANOVA)), there were no significant changes in total cholesterol (TC), TG levels, high-density lipoprotein cholesterol (HDL-C), or low-density lipoprotein cholesterol (LDL-C) in either group. Serum free thyroxine (fT4) levels were significantly decreased in the CBZ group (baseline: 1.15 ± 0.06 ng/dl, 1 month: 1.00 ± 0.16 ng/dl, 6 months: 0.98 ± 0.14 ng/dl, $p = 0.03$, ANOVA). In contrast, there were no significant changes in fT4 or thyroid-stimulating hormone (TSH) levels in the LEV group. The results of the present study suggest that LEV monotherapy does not affect lipid profile or thyroid function while CBZ monotherapy may cause thyroid dysfunction.

1. Introduction

Carbamazepine (CBZ) and levetiracetam (LEV) are among the first-line agents used in the treatment of partial seizures [1]. While previous studies have demonstrated that CBZ and LEV are equally effective for the treatment of newly diagnosed epilepsy in both adults and children [2,3], long-term adverse effects also play a role in the choice of antiepileptic drug (AED) [4]. Carbamazepine is associated with potent induction of the cytochrome P450 (CYP450) enzyme system as well as increases in serum lipid levels, particularly total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) [5]. Most previous studies were cross-sectional in nature [5–10]; however, a few prospective longitudinal studies have also reported that CBZ monotherapy increases serum TC, LDL-C, triglyceride (TG), and lipoprotein (a) levels in children [11–13]. Carbamazepine has also been associated with adverse effects on thyroid function [14]. Previous studies have reported that CBZ monotherapy is associated with a significant decrease in triiodothyronine (T3), thyroxine (T4), and free thyroxine (fT4) levels [14]. In contrast, dyslipidemia and altered levels of thyroid hormone have rarely been reported in patients taking LEV, and research regarding this matter remains inconclusive [15–20]. Although two cross-sectional studies and one longitudinal study analyzed the association between serum lipid levels and LEV, they have produced conflicting results [15–17]. Furthermore, no prospective studies have examined the association between thyroid hormone levels and LEV use [17–20].

The primary aim of the present prospective study was to evaluate changes in lipid levels in children undergoing CBZ or LEV monotherapy. We further aimed to examine changes in thyroid hormone levels in

Abbreviations: CBZ, carbamazepine; LEV, levetiracetam; CYP450, cytochrome P450; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; T3, triiodothyronine; T4, thyroxine; fT4, free thyroxine; AED, antiepileptic drug; HDL-C, high-density lipoprotein cholesterol; TSH, thyroid-stimulating hormone; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; CRP, C-reactive protein; LC/MS/MS, liquid chromatography tandem mass spectrometry.

* Corresponding author.
E-mail address: nishiyan0203@yahoo.co.jp (M. Nishiyama).

https://doi.org/10.1016/j.yebeh.2018.11.003
1525-5050/

these patients and to determine the potential associations involving lipid and thyroid hormone levels.

2. Materials and methods

2.1. Study design and patients

This prospective, multicenter, observational study was conducted with the approval of the Ethics Committee of Kobe University Graduate School of Medicine (No.1788). Written informed consent was obtained from the parents/guardians of each patient. Patients were recruited from Kobe University Hospital, Japanese Red Cross Society Himeji Hospital, Kobe City Hospital Organization Kobe City Medical Center West Hospital, Hyogo Prefectural Kobe Children's Hospital, Hyogo Prefectural Kaibara Hospital, and Saiseikai Hyogoken Hospital between September 2015 and December 2017. Inclusion criteria were as follows: (a) age between 4 and 15 years, (b) diagnosis of epilepsy with at least two focal seizures within a year [21], and (c) newly treated with LEV or CBZ monotherapy. Patients with (a) previous neurological history such as intellectual disability or chromosomal abnormality, (b) those diagnosed with structural/metabolic epilepsy [21], (c) those with other medical conditions requiring continuous medication, and those (d) with unbalanced diets or taking supplements were excluded. Following enrollment, patients were excluded from the main analysis if they had discontinued initial AED monotherapy or they had taken any medication known to affect liver or thyroid function prior to the final evaluation period.

For each enrolled patient, blood tests were performed between 8 AM and 10 AM after at least 10 h of fasting on three separate occasions. Values were obtained prior to AED treatment (baseline), after 1 month of AED initiation (defined as 4 to 12 weeks after AED initiation), and after 6 months of AED initiation (defined as 26 to 39 weeks after AED initiation). Type and dosage of AED were selected by the physician based on the type of epilepsy and the physician's experience, although the study recommended that doses of AED align with the ethical guidelines outlined in the package inserts for each medication. Antiepileptic drugs were discontinued, added, or altered based on the clinical judgment of the physician.

2.2. Outcomes and assessments

The change in serum lipid values (TG and TC) from pretreatment to 1 and 6 months was regarded as the primary outcome. Secondary outcomes included changes in other serum lipid values (high-density lipoprotein cholesterol [HDL-C], LDL-C), thyroid-stimulating hormone (TSH), and fT4 between baseline and 1 and 6 months. We also evaluated differences in patient demographics, the seizure-free rate between 1 month and 6 months, AED dosages and peak concentrations, adverse events, and other serum values (aspartate aminotransferase [AST], alanine aminotransferase [ALT], gamma-glutamyltransferase [GGT], uric acid, C-reactive protein [CRP], and glucose). Each variable was also compared between the LEV and CBZ groups. We also examined the correlation among changes in serum variables from pretreatment to 6 months and serum AED concentrations after 6 months. Triglyceride, TC, and AED concentrations after 6 months were selected for correlation analysis, along with variables exhibiting significant changes between baseline and 6 months.

All serum tests were performed in our hospital or by a commercial company (LSI Medience Co., Japan) in accordance with the manufacturer's instructions. Triglyceride and TC were measured with commercial enzymatic methods using a JCA-BM8040G system (JEOL Co., Ltd., Japan). Low-density lipoprotein cholesterol and HDL-C were directly measured using a JCS-BM8040G system (JEOL Co., Ltd., Japan). Serum TSH and fT4 were measured via chemiluminescent immunoassay using an ARCHITECT i2000SR system (Abbott Core Laboratory, U.S.A.). Serum CBZ concentration was assayed via enzyme immunoassay while serum LEV concentration was assayed via liquid chromatography tandem mass spectrometry (LC/MS/MS).

2.3. Statistics

All analyses were performed using JMP (version 11.0) statistical software (SAS, Inc., Japan). Data are presented as the mean ± standard deviation (SD). Student's t-test was applied when comparing values between two patient groups. Repeated-measures analyses of variance (ANOVA) were used to compare values among different study points (baseline, 1 month, 6 months). Associations among all parameters were examined using Spearman correlation coefficients. p values less than 0.05 were considered significant.

3. Results

3.1. Patient demographics and treatment

Among the 21 patients (LEV: 13 patients, CBZ: 8 patients) initially included in the study, all but one continued taking AED monotherapy during the study period. One patient discontinued taking LEV within 1 month from the start of treatment because of aggression, and he was thus, excluded from the main analysis. The remaining 20 patients completed the study (LEV: 12 patients; CBZ: 8 patients). We observed no significant differences in age, sex, height, weight, Rohrer index, or epilepsy syndrome between the LEV and CBZ groups (Table 1).

The mean initial dosage of LEV was 9.1 ± 2.1 mg/kg. Dosages of LEV after 1 month and 6 months were 13.2 ± 4.9 mg/kg and 16.9 ± 10.6 mg/kg, respectively (Table 2). The mean initial dosage of CBZ was 4.4 ± 1.7 mg/kg. Dosages of CBZ after 1 month and 6 months were 6.5 ± 2.3 mg/kg and 8.5 ± 4.2 mg/kg, respectively. Nine patients (75%) in the LEV group and three patients in the CBZ group (38%) remained seizure-free between 1 month and 6 months. With the exception of the one patient who discontinued taking LEV, no patient experienced severe adverse events. Although one patient in the LEV group experienced mild and temporary aggression, he continued taking the drug. Two patients of the LEV group and one patient of the CBZ group experienced mild somnolence. Dizziness and abnormal pitch perception were detected after 1 month in one patient in the CBZ group; however, both symptoms resolved after 6 months.

3.2. Serum variables

Serum lipid levels, thyroid hormone levels, and other values are shown in Table 2. With the exception of glucose, we observed no significant differences in serum variables between the LEV and CBZ groups at baseline. All but one patient (TG: 328 mg/dl in the LEV group) had serum TG, TC, HDL, and LDL values within normal limits prior to treatment. No significant changes in serum TG, TC, HDL-C, or LDL-C were noted in either group, although serum TG levels tended to be increased

Table 1
Demographic characteristics and baseline clinical data.

	LEV n = 12	CBZ n = 8	p
Age (years)	9.2 ± 2.8	8.8 ± 3.7	0.74
Sex (female:male)	6:6	5:3	0.67
Height (cm)	132.6 ± 18.8	128.3 ± 23.0	0.66
Weight (kg)	34.9 ± 16.3	29.3 ± 14.8	0.45
Rohrer index	141.8 ± 26.1	132.7 ± 23.4	0.44
Epilepsy syndrome			0.10
BECT, n (%)	2 (17)	3 (38)	
Occipital epilepsy, n (%)	0 (0)	2 (25)	
Frontal lobe epilepsy, n (%)	3 (25)	0 (0)	
Other focal epilepsy, n (%)	7 (58)	3 (38)	

BECT: benign epilepsy of childhood with centrotemporal spikes.

Table 2
Serum lipid profile, thyroid hormone levels, and other values in patients taking LEV or CBZ.

	LEV-treated patients			CBZ-treated patients		
	Baseline	After 1 month	After 6 months	Baseline	After 1 month	After 6 months
Duration after treatment (weeks)		6.0 ± 1.5	31.1 ± 4.2		7.0 ± 2.5	32.3 ± 3.2
Dosage of AED (mg/kg)		13.2 ± 4.9	16.9 ± 10.6		6.5 ± 2.3	8.7 ± 4.2
AED concentration (μg/ml)		9.2 ± 8.7	14.1 ± 15.2		5.1 ± 2.2	7.1 ± 4.1
Serum variables						
TG (mg/dl)	79.0 ± 81.8	51.3 ± 27.9	63.6 ± 51.2	58.3 ± 22.0	63.8 ± 21.6	92.3 ± 63.6
TC (mg/dl)	174.7 ± 17.8	176.1 ± 23.7	173.1 ± 20.5	163.8 ± 24.2	166.1 ± 19.8	159.1 ± 33.1
HDL-C (mg/dl)	64.0 ± 17.2	63.8 ± 13.6	64.3 ± 16.5	60.8 ± 19.2	59.0 ± 12.2	62.3 ± 19.6
LDL-C (mg/dl)	98.0 ± 14.2	101.6 ± 22.5	96.7 ± 18.1	90.3 ± 19.2	93.3 ± 17.3	83.1 ± 18.7
TSH (μU/ml)	1.60 ± 0.62	1.56 ± 0.51	1.35 ± 0.61	1.31 ± 0.82	2.13 ± 1.92	1.77 ± 1.12
fT4 (ng/dl)	1.20 ± 0.21	1.17 ± 0.14**	1.18 ± 0.14**	1.15 ± 0.06*	1.00 ± 0.16*,**	0.98 ± 0.14*,**
AST (U/l)	23.7 ± 3.8	24.8 ± 6.2	23.7 ± 6.2	24.0 ± 4.1	22.6 ± 3.5	25.1 ± 4.7
ALT (U/l)	14.8 ± 7.1	19.2 ± 23.6	14.5 ± 10.5	14.1 ± 9.0	14.5 ± 8.0	17.3 ± 11.4
GGT (U/l)	12.7 ± 2.5	12.5 ± 2.5**	12.9 ± 3.6**	12.3 ± 3.6*	24.0 ± 10.4*,**	34.2 ± 23.0*,**
Uric acid (mg/dl)	4.3 ± 0.9	4.3 ± 1.0	4.4 ± 0.7	4.6 ± 1.2	4.0 ± 1.1	4.0 ± 0.9
CRP (mg/dl)	0.13 ± 0.36	0.15 ± 0.23	0.06 ± 0.09	0.05 ± 0.08	0.02 ± 0.03	0.55 ± 0.81
Glucose (mg/dl)	95.6 ± 5.1**	92.5 ± 3.0	93.7 ± 7.3	90.6 ± 2.8**	89.0 ± 7.1	84.8 ± 14.4

Mean ± SD.
TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TSH, thyroid-stimulating hormone; fT4, free thyroxine; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; CRP, C-reactive protein.
* $p < 0.05$ with ANOVA among baseline, after 1 month, and after 6 months.
** $p < 0.05$ between LEV and CBZ groups.

in the CBZ group after 6 months (baseline: 58.3 ± 22.0 mg/dl, 1 month: 63.8 ± 21.6 mg/dl, 6 months: 92.3 ± 63.6 mg/dl, $p = 0.22$, ANOVA).

All patients had normal thyroid function prior to treatment. Neither serum TSH nor fT4 changed in the LEV group. However, serum fT4 levels were decreased in the CBZ group (baseline: 1.15 ± 0.06 ng/dl, 1 month: 1.00 ± 0.16 ng/dl, 6 months: 0.98 ± 0.14 ng/dl, $p = 0.03$, ANOVA). Moreover, after 1 month and 6 months, fT4 levels were significantly lower in the CBZ group than in the LEV group (after 1 month: 1.00 ± 0.16 ng/dl vs. 1.17 ± 0.14 ng/dl, $p = 0.02$; after 6 months: 0.98 ± 0.14 ng/dl vs. 1.18 ± 0.14 ng/dl, $p = 0.008$). However, all patients exhibited normal serum fT4 values (0.70–1.48 ng/dl) and remained clinically euthyroid during the study period. Among other serum variables, GGT was increased in the CBZ group (baseline: 12.3 ± 3.6 U/l, 1 month: 24.0 ± 10.4 U/l, 6 months: 34.2 ± 23.0 U/l, $p = 0.02$, ANOVA) and remained significantly higher in the CBZ group than in the LEV group (after 1 month: 24.0 ± 10.4 U/l vs. 12.5 ± 2.5 U/l, $p = 0.001$; after 6 months: 34.2 ± 23.0 U/l vs. 12.9 ± 3.6 U/l, $p = 0.005$). Changes in TG, fT4, and GGT after 1 month and 6 months relative to baseline are shown in Fig. 1.

We then examined correlations among the following parameters in both groups: changes in serum variables from pretreatment to 6 months (TG, TC, fT4, GGT) and AED concentrations after 6 months. No significant correlations between changes in serum variables and AED concentrations were observed in either group (data not shown). However, in the CBZ group, significant negative correlations were observed between changes in TG levels and changes in fT4 levels ($r = 0.898$, $p = 0.002$; Fig. 2).

4. Discussion

To the best of our knowledge, the present study is the first prospective longitudinal study to evaluate serum lipid and thyroid hormone levels in children treated with LEV. Indeed, we observed no alterations in lipid or thyroid hormone levels in children treated with LEV; however, in the CBZ group, serum fT4 values were decreased at 1 and 6 months after treatment while serum lipid levels remained unchanged.

To our knowledge, two cross-sectional studies and one longitudinal study have investigated the association between dyslipidemia and LEV monotherapy [15–17]. Two studies involving adults suggested that there is no association between serum lipid levels and LEV [15,16]. In contrast, one cross-sectional study involving children reported that LDL and HDL levels are higher in patients treated with LEV than in healthy children [17]. Considering the pharmacokinetic features of LEV, which does not induce liver enzyme increases and does not require dose adjustment in patients with mild to moderate liver dysfunction [22], our findings support the notion that LEV does not affect serum lipid levels.

In contrast to the findings of previous studies [5–8,11–13], our results indicated that CBZ did not increase serum TC and LDL-C levels. Because previous systemic reviews and prospective studies have reported that CBZ use is associated with dyslipidemia [5,11–13,23,24], these findings may have been due to the low number of patients in the present study. Indeed, although the result was not significant, TG levels tended to increase in patients treated with CBZ. Significant increases (>50 mg/dl) in TG levels were observed in two patients taking CBZ, suggesting that noticeable increases may occur in select patients [5].

In the present study, neither fT4 nor TSH levels were changed after 1 and 6 months of LEV treatment, consistent with the findings of two previous retrospective longitudinal studies [18,20]. However, two previous cross-sectional studies have reported an association between LEV and low fT4 levels [17,19]. El-Farahaty et al. reported that fT4 levels were lower in children treated with LEV than in healthy children or those treated with CBZ [17]. Shih et al. reported that, among 298 adults with epilepsy, LEV was associated with low fT4 (odds ratio: 2.432 [95% confidence interval: 1.325–4.464]) [19]. Given these conflicting results and the low number of patients in the present study, further investigation is required to determine the association between fT4 and LEV use.

We also observed that serum fT4 was significantly decreased at 1 and 6 months in patients treated with CBZ. Our findings are consistent with those of a previous meta-analysis, which reported that CBZ use was associated with low serum fT4 without alterations in TSH levels in children [14]. Previous researchers have proposed several mechanisms to explain the association between CBZ and abnormal thyroid function [25–27]. Some authors have suggested that low fT4 levels are caused by a CBZ-induced increase in hepatic clearance of thyroid hormones [27]. However, this explanation is insufficient, as valproate—which does not induce such increases—has also been associated with low fT4 [14]. Others have speculated that CBZ increases competitive binding of thyroid hormones to thyroxine-binding globulin [26,27], along with interference with the hypothalamic–pituitary axis [25,27]. Because we observed no association between changes in fT4 and GGT levels in our study, altered levels of thyroid hormones cannot be explained by the enzyme-inducing effect of CBZ alone.



Fig. 1. Changes in serum variables (A; change in fT4, B; change in TG, C; change in GGT) in each patient after 1 month and 6 months relative to baseline. The diagonal-lined bar represents the change after 1 month while the filled bar represents the change after 6 months. Patients treated with LEV are displayed on the left while patients treated with CBZ are displayed on the right. fT4: free thyroxine; TG: triglyceride; GGT: gamma-glutamyltransferase; LEV: levetiracetam; CBZ: carbamazepine.



Fig. 2. Scatterplot representing the negative correlation between changes in fT4 and changes in TG after 6 months of CBZ monotherapy in eight patients with epilepsy ($r = 0.898$, $p = 0.002$). fT4: free thyroxine; TG: triglyceride; CBZ: carbamazepine.

In addition, we observed no correlation between AED concentration and changes in TG, TC, fT4, or GGT levels, consistent with the findings of several previous studies [27–29]. However, one study did report a negative correlation between thyroid hormone levels and CBZ concentration [30]. In our study, changes in TG levels exhibited a strong negative correlation with changes in fT4 in children treated with CBZ. Indeed, few studies have investigated the correlation between serum lipid and thyroid hormone levels in children treated with AEDs [31]. Garoufi et al. reported a significant positive correlation between TC and TSH levels in patients treated with oxcarbazepine monotherapy [31]. We hypothesized that TG levels may increase because of decreases in fT4, as proposed in previous reports [31]. In addition, similar to findings observed in previous studies, our patients remained clinically euthyroid despite these changes [27,29,31].

The present study possesses several limitations of note, including its small sample size. For ethical reasons, we were unable to include a control group of children with epilepsy who had not been treated with AED. In addition, while baseline clinical data did not significantly differ between the LEV and CBZ groups, we did not evaluate Tanner developmental stage or endocrinological function including levels of sex hormones. Finally, the dosage and concentration of AED were relatively low in the LEV group. However, because the seizure-free rate in the LEV group was similar to that reported in previous studies [2,3], the treatment strategy selected by the physician was considered clinically appropriate.

In conclusion, the results of the present nonrandomized study suggest that LEV monotherapy does not affect lipid profile or thyroid function while CBZ monotherapy may cause thyroid laboratory dysfunction. Based on these preliminary findings, LEV monotherapy may have advantages over CBZ monotherapy in children with non-structural/metabolic epilepsy. However, large, prospective studies are required to verify this hypothesis.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

This work was partly supported by a Grant-in-Aid for Young Scientists (B) (18K15711) of JSPS KAKENHI. The authors thank all participating physicians and nurses who took care of the patients. We also thank the children and their parents for their kind collaboration. We also thank Dr. Kuniyasu Sakai at Hyogo Prefectural Kaibara Hospital, Junji Eguchi at Kobe City Hospital Organization, Kobe City Medical Center West Hospital, and Dr. Takahiro Okutani at Saiseikai

Hyogoken Hospital for their kind collaboration. We also thank Dr. Masaaki Matsumoto, Dr. Masashi Nagai, Dr. Ryosuke Bo, and Dr. Hiroyuki Awano at Kobe University Graduate School of Medicine for their input regarding endocrinological matters.

References

[1] Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH. Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance. BMJ 2012; 344:e281. https://doi.org/10.1136/bmj.e281.
[2] Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68:402–8. https://doi.org/10.1212/01.wnl.0000252941.50833.4a.
[3] Jung da E, Yu R, Yoon JR, Eun BL, Kwon SH, Lee YJ, et al. Neuropsychological effects of levetiracetam and carbamazepine in children with focal epilepsy. Neurology 2015; 84:2312–9. https://doi.org/10.1212/wnl.0000000000001661.
[4] Mintzer S. Metabolic consequences of antiepileptic drugs. Curr Opin Neurol 2010; 23:164–9. https://doi.org/10.1097/WCO.0b013e32833735e7.
[5] Vyas MV, Davidson BA, Escalaya L, Costella J, Saposnik G, Burneo JG. Antiepileptic drug use for treatment of epilepsy and dyslipidemia: systematic review. Epilepsy Res 2015;113:44–67. https://doi.org/10.1016/j.eplepsyres.2015.03.002.
[6] Eiris JM, Lojo S, Del Rio MC, Novo I, Bravo M, Pavon P, et al. Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 1995;45:1155–7.
[7] Verrotti A, Domizio S, Angelozzi B, Sabatino G, Morgese G, Chiarelli F. Changes in serum lipids and lipoproteins in epileptic children treated with anticonvulsants. J Paediatr Child Health 1997;33:242–5.
[8] Castro-Gago M, Novo-Rodriguez MI, Blanco-Barca MO, Urisarri-Ruiz de Cortazar A, Rodriguez-Garcia J, Rodriguez-Segade S, et al. Evolution of serum lipids and lipoprotein (a) levels in epileptic children treated with carbamazepine, valproic acid, and phenobarbital. J Child Neurol 2006;21:48–53.
[9] Chuang YC, Chuang HY, Lin TK, Chang CC, Lu CH, Chang WN, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 2012;53:120–8. https://doi.org/10.1111/j.1528-1167.2011.03316.x.
[10] Yamamoto Y, Terada K, Takahashi Y, Imai K, Kagawa Y, Inoue Y. Influence of antiepileptic drugs on serum lipid levels in adult epilepsy patients. Epilepsy Res 2016;127: 101–6. https://doi.org/10.1016/j.eplepsyres.2016.08.027.
[11] Voudris KA, Attilakos A, Katsarou E, Drakatos A, Dimou S, Mastroyianni S, et al. Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy. Epilepsy Res 2006;70:211–7. https://doi.org/10.1016/j.eplepsyres.2006.05.002.
[12] Aggarwal A, Singh V, Batra S, Faridi MM, Sharma S. Effect of carbamazepine therapy on serum lipids in children with partial epilepsy. Pediatr Neurol 2009;40:94–7. https://doi.org/10.1016/j.pediatrneurol.2008.10.003.
[13] Sonmez FM, Demir E, Orem A, Yildirmis S, Orhan F, Aslan A, et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. J Child Neurol 2006;21:70–4.
[14] Zhang YX, Shen CH, Lai QL, Fang GL, Ming WJ, Lu RY, et al. Effects of antiepileptic drug on thyroid hormones in patients with epilepsy: a meta-analysis. Seizure 2016;35:72–9. https://doi.org/10.1016/j.seizure.2016.01.010.
[15] Svalheim S, Luef G, Rauchenzauner M, Morkrid L, Gjerstad L, Tauboll E. Cardiovascular risk factors in epilepsy patients taking levetiracetam, carbamazepine or lamotrigine. Acta Neurol Scand Suppl 2010:30–3. https://doi.org/10.1111/j.1600-0404.2010.01372.x.
[16] Kim DW, Lee SY, Shon YM, Kim JH. Effects of new antiepileptic drugs on circulatory markers for vascular risk in patients with newly diagnosed epilepsy. Epilepsia 2013; 54:e146–9. https://doi.org/10.1111/epi.12338.
[17] El-Farahaty RM, El-Mitwalli A, Azzam H, Wasel Y, Elrakhawy MM, Hasaneen BM. Atherosclerotic effects of long-term old and new antiepileptic drugs monotherapy: a cross-sectional comparative study. J Child Neurol 2014. https://doi.org/10.1177/0883073814551388.
[18] Yilmaz U, Yilmaz TS, Akinci G, Korkmaz HA, Tekgul H. The effect of antiepileptic drugs on thyroid function in children. Seizure 2014;23:29–35. https://doi.org/10.1016/j.seizure.2013.09.006.
[19] Shih FY, Chuang YC, Chuang MJ, Lu YT, Tsai WC, Fu TY, et al. Effects of antiepileptic drugs on thyroid hormone function in epilepsy patients. Seizure 2017;48:7–10. https://doi.org/10.1016/j.seizure.2017.03.011.
[20] Aygun F, Ekici B, Aydinli N, Aydin BK, Bas F, Tatli B. Thyroid hormones in children on antiepileptic therapy. Int J Neurosci 2012;122:69–73. https://doi.org/10.3109/00207454.2011.627486.
[21] Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010;51:676–85. https://doi.org/10.1111/j.1528-1167.2010.02522.x.
[22] Wright C, Downing J, Mungall D, Khan O, Williams A, Fonkem E, et al. Clinical pharmacology and pharmacokinetics of levetiracetam. Front Neurol 2013;4:192. https://doi.org/10.3389/fneur.2013.00192.
[23] Mintzer S, Skidmore CT, Abidin CJ, Morales MC, Chervoneva I, Capuzzi DM, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009;65:448–56. https://doi.org/10.1002/ana.21615.
[24] Mintzer S, Miller R, Shah K, Chervoneva I, Nei M, Skidmore C, et al. Long-term effect of antiepileptic drug switch on serum lipids and C-reactive protein. Epilepsy Behav 2016;58:127–32. https://doi.org/10.1016/j.yebeh.2016.02.023.
[25] Bentsen KD, Gram L, Veje A. Serum thyroid hormones and blood folic acid during monotherapy with carbamazepine or valproate. A controlled study. Acta Neurol Scand 1983;67:235–41.
[26] Roy-Byrne PP, Joffe RT, Uhde TW, Post RM. Carbamazepine and thyroid function in affectively ill patients. Clinical and theoretical implications. Arch Gen Psychiatry 1984;41:1150–3.
[27] Isojarvi JI, Pakarinen AJ, Myllyla VV. Thyroid function with antiepileptic drugs. Epilepsia 1992;33:142–8.
[28] Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol 2001;25:43–6.
[29] Verrotti A, Laus M, Scardapane A, Franzoni E, Chiarelli F. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. Eur J Endocrinol 2009;160:81–6. https://doi.org/10.1530/eje-08-0325.
[30] Tanaka K, Kodama S, Yokoyama S, Komatsu M, Konishi H, Momota K, et al. Thyroid function in children with long-term anticonvulsant treatment. Pediatr Neurosci 1987;13:90–4.
[31] Garoufi A, Koemtzidou E, Katsarou E, Dinopoulos A, Kalimeraki I, Fotinou A, et al. Lipid profile and thyroid hormone concentrations in children with epilepsy treated with oxcarbazepine monotherapy: a prospective long-term study. Eur J Neurol 2014;21:118–23. https://doi.org/10.1111/ene.12262.